The price of Paianprilizumab is around 4,875 yuan/branch (10mL). Paianprilizumab is a domestic PD-1 immunotherapy drug, which can be used for third-line nasopharyngeal cancer, first-line non-small cell lung cancer, liver cancer and other cancer treatments, and the price stays around RMB 4,875/branch (10mL), but the drug has charitable gift and medical insurance reimbursement benefits, so the specific price may be reduced. Amprolizumab is currently the only monoclonal antibody drug of IgG1 subtype and modified by Fc segment, the antibody structure is stable, it can effectively remove ADCC, ADCP and other reactions, and durably block the binding of PD-1, PD-L1, so as to play a role in shrinking tumors, killing cancer cells, etc., but it will be accompanied by fever, anemia, bone pain, rash and other adverse reactions. The drug should be used under the guidance of a doctor, do not use the drug blindly, and during the use of the drug need to follow the doctor’s instructions to regularly monitor the indicators, in order to avoid the emergence of serious adverse reactions.